PBLS Parabilis Medicines, Inc. Common Stock
XNAS
25.03
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
PBLS
$25.03
—
Key stats
$25.03
Pre-market
$25.25
+0.88%
- 52-Week Range
- $22.66 – $42.48
- YTD
- -20.79%
- Straddle Price
- $5.03
- P/C Vol Ratio
- 0.85
- Market Cap
- $3.0B
- Open
- $25.01
- Day Range
- $23.06 – $25.59
- Volume
- 1,427,694
- Prev Close
- $24.44
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.96% (VRP-adj) |
| WACC | 10.11% |
| Volatility Risk Premium | +50.7pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $33.87 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $27.70 |
| Bollinger Width / SMA20 | 127.6% (drives anchor stability) |
| Net Debt | $0.0B |
Peers used for multiples: BTSG, EXEL, LGND, LLY, MMED, ROIV, RPRX, RVMD
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 32.5× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 22.3× · 5 peers |
| Peer P/B | n/a | 0% | median 6.2× · 8 peers |
| Peer P/S | n/a | 0% | median 11.2× · 7 peers |
| Market Anchor (SMA50) | $33.87 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $24.37 | 0% | 8 strikes · skew -0.05 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $3.0B
- List Date
- 2026-06-10
- CIK
- 0001657677
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.40) (8 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.parabilismed.com
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multi…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -- | -- |
| Mar | -- | -- |
| Apr | -- | -- |
| May | -- | -- |
| Jun | -13.39% | -13.39% |
| Jul | 20.13% | 20.13% |
| Aug | 14.87% | 14.87% |
| Sep | -18.19% | -18.19% |
| Oct | -17.77%* | -17.77% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | -19.60% | -19.60% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $27.70
SMA 50: $33.87
SMA 200: —
Current: $25.03
EMA 12: $26.57
EMA 26: $28.93
MACD: -2.3598 | Signal: 0.0913
BEARISH
ADX (14): 33.35
TREND
+DI: 11.33
−DI: 27.58
Momentum Oscillators
RSI (14): 38.08
NEUTRAL
Stoch %K: 35.38
Stoch %D: 45.04
Williams %R: -69.22
Volume & Volatility
BB Upper: $32.59
BB Lower: $22.80
NEUTRAL
OBV: 5,320,279
Vol SMA 20: 1,110,955
Vol ROC: 18.62%
ATR: $2.62
True Range: $2.53
HV 20: 82.7%
HV 30: 93.9%
HV 60: 74.3%
Data Summary
Data Points: 96
Last Updated:
Date Range: 2026-06-10T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: PBLS
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical momentum signals are bullish, with a strong MACD crossover and rising RSI.
- News headlines suggest positive sentiment, with recent appointments and announcements.
Primary Risks:
- High volatility, as indicated by the beta value (-0.74).
- Market volatility regime is high, which may amplify price movements.
Investment Thesis: PBLS has been trending upwards, but recent news events have caused a slight pullback. The stock's negative beta means it moves opposite to the market, which could create opportunities for contrarian investors. However, the high volatility and risk metrics suggest caution is advised.
Recent News Sentiment Impact: The recent headlines are generally positive, with two out of three articles having a positive sentiment (66%). This may have contributed to the stock's recent pullback as traders react to the news.
Technical Analysis
Trend Direction: Medium-term uptrend (1-3 months)
Support/Resistance Levels:
- Lower Bollinger Band: $36.07
- Middle Line SMA 50: $34.37
Momentum Signals:
- RSI interpretation: Neutral zone (30-70), indicating no clear buy or sell signal.
- MACD signal: Bullish crossover, suggesting continued upward momentum.
- Bollinger Bands position: Neutral, with price within the middle band.
Volume Analysis: Volume trends are generally positive, with rising OBV and a high volume rate of change.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have dominated recent activity, focusing on appointments and announcements.
Sentiment Assessment: Overall sentiment is 66% positive, indicating a bullish tone.
Catalyst Identification: No upcoming earnings or events have been identified that could significantly impact the stock's price.
Market Narrative: The market narrative suggests that PBLS has been trending upwards due to recent news events, but may be experiencing some volatility as traders react to these developments.
Risk & Volatility Assessment
Beta Interpretation: Negative beta (-0.74) indicates the stock moves opposite to the market, which can amplify price movements.
Volatility Regime: High volatility regime, with a high HV60 value (63.8%).
Options Market Signals: No options data available.
Downside Protection: Support levels are present at $36.07 and $34.37, but caution is advised due to the high volatility.
Market Context & Positioning
Sector Performance: PBLS' sector is performing relatively well, with a moderate strength indicator.
Institutional Activity: No clear institutional activity patterns have been identified.
Correlation Analysis: The stock's correlation with the market (R-squared) is -0.15, indicating a strong inverse relationship.
Relative Valuation: PBLS is trading within its normal range, with no clear value or overvaluation signals.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $36.07
- Middle Line SMA 50: $34.37
Breakout/Breakdown Levels: No clear levels have been identified that could trigger significant price movements.
Time-Sensitive Catalysts: No upcoming events or earnings have been identified that could impact the stock's price.
Risk Management: Consider using a stop-loss level at $36.07, and position sizing to manage risk.
This comprehensive analysis provides an objective assessment of PBLS' technical indicators, news sentiment, and market context. While the stock has shown bullish momentum signals, the high volatility and negative beta suggest caution is advised.
Generated
News
All PBLS news →
PBLS Options Activity & IV Rank
Volatility Metrics
Current IV: 89.0%
7-DTE IV: —
Expected Move: $5.03
7-DTE Move: $5.03
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 33
Put Volume: 28
P/C Volume: 0.848
NEUTRAL
Call OI: 115
Put OI: 65
P/C OI: 0.565
Total OI: 180
ATM Options Pricing
ATM Call: $2.48
ATM Put: $2.55
Call %: 9.9%
Put %: 10.2%
Chain Summary
Chain Volume: 134
Chain OI: 495
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Not enough history yet to rank today's net dealer gamma against this name's own record.
Gamma percentile
—
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+0.97
δ-sensitivity to IV
Charm tilt
-0.99
δ-decay vs time
Vanna tilt +0.97: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.99: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 96.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$5.03Oct 26
Beta Analysis
Risk Metrics
Beta: 0.1550
Alpha: -36.50%
Correlation: 0.0246
R-Squared: 0.1%
Stock Volatility: 74.3%
Market Volatility: 11.8%
Analysis Details
Benchmark: SPY
Data Points: 95
Period: 252 trading days
Data Points: 95
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own PBLS
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| ICONIQ Capital Family office | $9.6M | #24 of 76 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PBLS Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
PBLS Insider Trading (Form 4)
Latest: 2026-08-25Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Craig Tendler | Director | Grant (A) | +20,294 opt | — | EDGAR | |
| 2026-07-22 | RA Capital Healthcare Fund LP | Director | Buy (P) | +1,222,965 | $28.29 | $34.60M | EDGAR |
| 2026-06-29 | Soleus Capital Management, L.P. | 10%+ Owner | Mixed | +9,243,630 | $14.60 | $134.97M | EDGAR |
| 2026-06-16 | Alan Sebulsky | Director | Buy (P) | +17,500 | $27.06 | $473.5K | EDGAR |
| 2026-06-15 | Alan Sebulsky | Director | Buy (P) | +12,500 | $20.00 | $250.0K | EDGAR |
| 2026-06-15 | Alexis Borisy | Director | Conv (C) | +105,414 | — | EDGAR | |
| 2026-06-15 | Edward M Fitzgerald | Director | Conv (C) | +14,688 | — | EDGAR | |
| 2026-06-15 | Rajeev M. Shah | Director | Mixed | +144,666,855 | $20.00 | $2.12B | EDGAR |
| 2026-06-11 | Richard Klausner | Director | Grant (A) | +20,215 opt | — | EDGAR | |
| 2026-06-11 | Alexis Borisy | Director | Grant (A) | +20,215 opt | — | EDGAR | |
| 2026-06-11 | Barbara Weber | Director | Grant (A) | +20,215 opt | — | EDGAR | |
| 2026-06-11 | Alan Sebulsky | Director | Grant (A) | +39,792 opt | — | EDGAR | |
| 2026-06-11 | Jake Simson | Director | Grant (A) | +20,215 opt | — | EDGAR | |
| 2026-06-11 | Edward M Fitzgerald | Director | Grant (A) | +20,215 opt | — | EDGAR | |
| 2026-06-11 | Krishna Yeshwant | Director | Grant (A) | +20,215 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
PBLS Insider Holdings
7 insiders · @ $25.03
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Healthcare Fund LP | Director | 26,444,713 | $661.91M | $34.60M | 1 | 2026-07-22 |
| 2 | Rajeev M. Shah | Director | 26,285,093 | $657.92M | $2.12B | 2 | 2026-06-15 |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | 533,220 | $13.35M | $0 | 1 | 2026-06-11 |
| 4 | Soleus Capital Management, L.P. | 10%+ Owner | 527,070 | $13.19M | $90.00M | 1 | 2026-06-29 |
| 5 | Alexis Borisy | Director | 105,414 | $2.64M | $0 | 2 | 2026-06-15 |
| 6 | Alan Sebulsky | Director | 25,935 | $649.2K | $723.5K | 3 | 2026-06-16 |
| 7 | Edward M Fitzgerald | Director | 14,688 | $367.6K | $0 | 2 | 2026-06-15 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
PBLS Board & Officers
As of SEC filings through Aug 25, 2026Directors 14
- Alan Sebulsky · since Jun 9, 2026
- Alexis Borisy · since Jun 9, 2026
- Barbara Weber · since Jun 9, 2026
- Edward M Fitzgerald · since Jun 9, 2026
- Jake Simson · since Jun 9, 2026
- Krishna Yeshwant · since Jun 9, 2026
- Mathai Mammen · since Jun 9, 2026
- Peter Kolchinsky · since Jun 9, 2026
- RA Capital Healthcare Fund LP (entity) · since Jun 9, 2026
- RA Capital Nexus Fund III, L.P. (entity) · since Jun 9, 2026
- Ra Capital Management, L.p. (entity) · since Jun 9, 2026
- Rajeev M. Shah · since Jun 9, 2026
- Richard Klausner · since Jun 9, 2026
- Craig Tendler · since Aug 22, 2026
Officers 6
- Mathai Mammen · President & CEO · since Jun 9, 2026
- Thomas Rodolpho Kotarakos · Chief Financial Officer · since Jun 9, 2026
- Mohammed Fawzi Benzaghou · Chief Medical Officer · since Jun 9, 2026
- Teresa Jurgensen · General Counsel · since Jun 9, 2026
- Helen Huei-in Ho · since Jun 9, 2026
- Rohin Mhatre · since Jun 9, 2026
10% owners 4
- Peter Kolchinsky · listed since Jun 2026
- RA Capital Healthcare Fund LP (entity) · listed since Jun 2026
- Ra Capital Management, L.p. (entity) · listed since Jun 2026
- Rajeev M. Shah · listed since Jun 2026
Changes in the last 10 years (48)
| Aug 22, 2026 | Craig Tendler became a director |
| Jun 29, 2026 | Soleus Private Equity GP III, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Soleus Private Equity Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Soleus PE GP III, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Soleus GP, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Soleus Capital Management, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 29, 2026 | Guy Levy reported in an SEC filing no longer being a 10% owner |
| Jun 15, 2026 | Rajeev M. Shah first listed as a 10% owner in an SEC filing |
| Jun 15, 2026 | Ra Capital Management, L.p. first listed as a 10% owner in an SEC filing |
| Jun 15, 2026 | RA Capital Healthcare Fund LP first listed as a 10% owner in an SEC filing |
| Jun 15, 2026 | Peter Kolchinsky first listed as a 10% owner in an SEC filing |
| Jun 11, 2026 | James E Flynn reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2026 | Deerfield Private Design Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2026 | Deerfield Mgmt III, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2026 | Deerfield Mgmt HIF, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2026 | Deerfield Management Company, L.p. reported in an SEC filing no longer being a 10% owner |
| Jun 11, 2026 | Deerfield Healthcare Innovations Fund, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 9, 2026 | Thomas Rodolpho Kotarakos became Chief Financial Officer |
| Jun 9, 2026 | Teresa Jurgensen became General Counsel |
| Jun 9, 2026 | Soleus Private Equity GP III, LLC became a 10% owner |
| Jun 9, 2026 | Soleus Private Equity Fund III, L.P. became a 10% owner |
| Jun 9, 2026 | Soleus PE GP III, LLC became a 10% owner |
| Jun 9, 2026 | Soleus GP, LLC became a 10% owner |
| Jun 9, 2026 | Soleus Capital Management, L.P. became a 10% owner |
| Jun 9, 2026 | Rohin Mhatre became an officer |
| Jun 9, 2026 | Richard Klausner became a director |
| Jun 9, 2026 | Rajeev M. Shah became a director |
| Jun 9, 2026 | Ra Capital Management, L.p. became a director |
| Jun 9, 2026 | RA Capital Nexus Fund III, L.P. became a director |
| Jun 9, 2026 | RA Capital Healthcare Fund LP became a director |
| Jun 9, 2026 | Peter Kolchinsky became a director |
| Jun 9, 2026 | Mohammed Fawzi Benzaghou became Chief Medical Officer |
| Jun 9, 2026 | Mathai Mammen became a director |
| Jun 9, 2026 | Mathai Mammen became President & CEO |
| Jun 9, 2026 | Krishna Yeshwant became a director |
| Jun 9, 2026 | James E Flynn became a 10% owner |
| Jun 9, 2026 | Jake Simson became a director |
| Jun 9, 2026 | Helen Huei-in Ho became an officer |
| Jun 9, 2026 | Guy Levy became a 10% owner |
| Jun 9, 2026 | Edward M Fitzgerald became a director |
| Jun 9, 2026 | Deerfield Private Design Fund III, L.P. became a 10% owner |
| Jun 9, 2026 | Deerfield Mgmt III, L.P. became a 10% owner |
| Jun 9, 2026 | Deerfield Mgmt HIF, L.P. became a 10% owner |
| Jun 9, 2026 | Deerfield Management Company, L.p. became a 10% owner |
| Jun 9, 2026 | Deerfield Healthcare Innovations Fund, L.P. became a 10% owner |
| Jun 9, 2026 | Barbara Weber became a director |
| Jun 9, 2026 | Alexis Borisy became a director |
| Jun 9, 2026 | Alan Sebulsky became a director |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
27 ETFs hold PBLS
25 shown · $140.79M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $36.2M | — | 2026-09-30 |
| 2 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $25.6M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $24.4M | $74.6B | 2026-10-23 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.03% | $16.7M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $12.9M | — | 2026-09-30 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.04% | $7.4M | — | 2026-09-30 |
| 7 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.04% | $5.5M | $13.7B | 2026-10-23 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.03% | $3.6M | $13.9B | 2026-10-23 |
| 9 | FBCG Fidelity Blue Chip Growth ETF | Nport | 0.03% | $2.2M | — | 2026-07-31 |
| 10 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.2M | $96.5B | 2026-10-23 |
| 11 | FPX First Trust US Equity Opportunities ETF | First Trust | 0.09% | $1.2M | $1.4B | 2026-10-23 |
| 12 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $925,958 | $10.7B | 2026-10-23 |
| 13 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.05% | $850,938 | — | 2026-09-30 |
| 14 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $567,399 | $6.6B | 2026-10-23 |
| 15 | RSSL Global X Russell 2000 ETF | Global X | 0.03% | $476,546 | — | 2026-10-26 |
| 16 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $459,422 | — | 2026-09-30 |
| 17 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $261,532 | $20.4B | 2026-10-23 |
| 18 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $108,430 | — | 2026-09-30 |
| 19 | RFLR Innovator U.S. Small Cap Managed Floor ETF | Innovator | 0.07% | $70,535 | $95.0M | 2026-10-26 |
| 20 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.03% | $56,668 | — | 2026-10-26 |
| 21 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $45,923 | $14.7B | 2026-10-23 |
| 22 | URTY ProShares UltraPro Russell2000 | ProShares | 0.02% | $43,477 | — | 2026-10-26 |
| 23 | UWM ProShares Ultra Russell2000 | ProShares | 0.01% | $30,487 | — | 2026-10-26 |
| 24 | KBFR Innovator U.S. Small Cap Managed 10 Buffer ETF | Innovator | 0.07% | $9,837 | $13.3M | 2026-10-26 |
| 25 | FSEG Fidelity Enhanced Small Cap Growth ETF | Fidelity | 0.09% | $7,063 | $7.6M | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
8.26M
SI % of Float
8.17%
Days to Cover
4.84
Short Vol Ratio
75.7%
Free Float
101.16M
Float %
83.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-19